Annovis Bio, Inc.
(NYSE : ANVS)

( )
ANVS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.48%166.090.7%$1108.87m
PFEPfizer Inc. -0.72%49.750.9%$939.86m
ABBVAbbVie, Inc. -0.22%142.291.9%$831.12m
MRKMerck & Co., Inc. -0.47%90.590.7%$806.25m
LLYEli Lilly & Co. 1.90%313.931.1%$798.53m
BMYBristol-Myers Squibb Co. -1.36%74.541.0%$648.45m
SIGASIGA Technologies, Inc. 5.66%26.150.0%$514.56m
AZNAstraZeneca Plc 0.26%66.811.0%$373.58m
GBTGlobal Blood Therapeutics, Inc. 0.43%67.045.6%$334.64m
ALNYAlnylam Pharmaceuticals, Inc. -1.21%231.018.2%$285.62m
GSKGSK Plc -3.08%34.920.3%$275.20m
HZNPHorizon Therapeutics Plc -3.81%64.905.4%$222.52m
KRTXKaruna Therapeutics, Inc. -1.34%273.710.0%$217.12m
CCXIChemoCentryx, Inc. 0.18%50.812.9%$205.42m
RGENRepligen Corp. 1.74%255.736.7%$190.66m

Company Profile

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.